Measurable residual disease testing in acute myeloid leukaemia. (Q30234914)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28386105 AND SRC:MED&resulttype=core&format=json

16 March 2020

title

Measurable residual disease testing in acute myeloid leukaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28386105 AND SRC:MED&resulttype=core&format=json

16 March 2020

1 reference

Christopher S Hourigan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28386105 AND SRC:MED&resulttype=core&format=json

16 March 2020

author name string

R P Gale

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28386105 AND SRC:MED&resulttype=core&format=json

16 March 2020

N J Gormley

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28386105 AND SRC:MED&resulttype=core&format=json

16 March 2020

G J Ossenkoppele

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28386105 AND SRC:MED&resulttype=core&format=json

16 March 2020

R B Walter

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28386105 AND SRC:MED&resulttype=core&format=json

16 March 2020

publication date

7 April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28386105 AND SRC:MED&resulttype=core&format=json

16 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28386105 AND SRC:MED&resulttype=core&format=json

16 March 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28386105 AND SRC:MED&resulttype=core&format=json

16 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28386105 AND SRC:MED&resulttype=core&format=json

16 March 2020

page(s)

1482-1490

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28386105 AND SRC:MED&resulttype=core&format=json

The total cellularity of the bone marrow in man.

16 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

What does MRD in leukemia really mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Genomic Classification and Prognosis in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

21 January 2018

Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Minimal residual disease in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Tumor heterogeneity makes AML a "moving target" for detection of residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Concise reviews: A stem cell apostasy: a tale of four H words

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Standardizing Flow Cytometry Immunophenotyping Analysis from the Human ImmunoPhenotyping Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance rounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Standardized definitions of molecular response in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

New score predicting for prognosis in PML-RARA , AML1-ETO , or CBFBMYH11 acute myeloid leukemia based on quantification of fusion transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Assessment of Minimal Residual Disease in Standard-Risk AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

A multigene array for measurable residual disease detection in AML patients undergoing SCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Functional heterogeneity of genetically defined subclones in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Optimizing cancer genome sequencing and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Precision medicine in acute myeloid leukemia: Hope, hype or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

The Origin and Evolution of Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Modeling minimal residual disease (MRD)-testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

The concept of treatment-free remission in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Towards individualized follow-up in adult acute myeloid leukemia in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Common Leukemia- and Lymphoma-Associated Genetic Aberrations in Healthy Individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Isolated clonal cytogenetic abnormalities after high-dose therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Leukemia- and lymphoma-associated genetic aberrations in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

ICSH: on board for new projects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

When the Minimal Becomes Measurable.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Minimal Residual Disease–Guided Treatment Deintensification for Children With Acute Lymphoblastic Leukemia: Results From the Malaysia-Singapore Acute Lymphoblastic Leukemia 2003 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

End points to establish the efficacy of new agents in the treatment of acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

New drug approvals in acute myeloid leukemia: what's the best end point?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Progression-free survival is a surrogate for survival in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

The Role of Physicians in the Era of Predictive Analytics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Persistence ofDNMT3Amutations at long-term remission in adult patients with AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

Relapse kinetics in acute myeloid leukaemias withMLLtranslocations or partial tandem duplications within theMLLgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

The effect of chemotherapy on acute leukemia in the human

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Aberrant marker expression patterns on the CD34 CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Tumor heterogeneity makes AML a "moving target" for detection of residual disease

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Measureable residual disease (MRD): much ado about nothing?

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Molecular monitoring in CML and the prospects for treatment-free remissions

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Assessment of Minimal Residual Disease in Standard-Risk AML

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Automated analysis of acute myeloid leukemia minimal residual disease using a support vector machine

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Reply to D. Przepiorka et al

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission

1 reference

https://api.crossref.org/works/10.1038/LEU.2017.113

7 January 2021

Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease

1 reference

12 December 2020

Minimal residual disease in acute leukaemia: preclinical studies in a relevant rat model (BNML).

1 reference

12 December 2020

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia

1 reference

12 December 2020

Minimal residual disease in leukemia: state of the art 1991

1 reference

12 December 2020

The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia

1 reference

12 December 2020

Therapy of molecular relapse in acute promyelocytic leukemia

1 reference

12 December 2020

Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance

1 reference

12 December 2020

Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical significance

1 reference

12 December 2020

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

1 reference

12 December 2020

Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.

1 reference

12 December 2020